Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

Executive Summary

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

You may also be interested in...



Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab

June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC098856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel